Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other financing activities (2016 - 2020)

Agios Pharmaceuticals (AGIO) has disclosed Other financing activities for 5 consecutive years, with $250.5 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Other financing activities changed N/A year-over-year to $250.5 million, compared with a TTM value of $250.5 million through Mar 2021, changed N/A, and an annual FY2020 reading of $250.5 million, changed N/A over the prior year.
  • Other financing activities was $250.5 million for Q2 2020 at Agios Pharmaceuticals, up from $203000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $250.5 million in Q2 2020 and bottomed at -$727000.0 in Q4 2017.
  • Average Other financing activities over 4 years is $27.8 million, with a median of $124000.0 recorded in 2016.
  • The sharpest move saw Other financing activities tumbled 785.85% in 2017, then soared 199.51% in 2018.
  • Year by year, Other financing activities stood at $106000.0 in 2016, then crashed by 785.85% to -$727000.0 in 2017, then soared by 127.92% to $203000.0 in 2018, then surged by 123317.24% to $250.5 million in 2020.
  • Business Quant data shows Other financing activities for AGIO at $250.5 million in Q2 2020, $203000.0 in Q2 2018, and $188000.0 in Q1 2018.